Global Outlook on PD-1 Resistant Head and Neck Cancer Treatment Strategies
According to Decision Advisors, the PD-1 Resistant Head and Neck Cancer Market Size is expected to grow from USD 1.62 billion in 2025 to USD 5.46 billion by 2035, at a CAGR of 12.92% during the forecast period 2025-2035. Fueled by the increase in HPV-related cases, strong research and development of new combinations (such as Monalizumab), and genomic profiling, high unmet need, combination therapies, rising incidence of HPV-related HNSCC, and precision medicine and biomarkers.